In summary, 5‐HT2CR agonists are effective at improving obesity and show therapeutic benefit with respect to glycaemic control and insulin sensitivity in obese individuals with prediabetes or type 2 diabetes. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.